Risk of false positive results to SARM S-4 in case of therapeutic use of antineoplastic/antiandrogen drug containing flutamide: a case study.

• Perrenoud L Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne-Geneva, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Chemin des Croisettes 22, 1066, Epalinges, Switzerland.
• Schweizer Grundisch C Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne-Geneva, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Chemin des Croisettes 22, 1066, Epalinges, Switzerland.
• Baume N Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne-Geneva, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Chemin des Croisettes 22, 1066, Epalinges, Switzerland.
• Saugy M Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne-Geneva, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Chemin des Croisettes 22, 1066, Epalinges, Switzerland.
• Nicoli R Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne-Geneva, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Chemin des Croisettes 22, 1066, Epalinges, Switzerland.

Androgen Antagonists

Angiotensin II Type 1 Receptor Blockers

Antineoplastic Agents

Flutamide

Humans